A recent SPECTRUM article discussed the FDA’s ‘breakthrough device’ designation for a hair-based diagnostic test for autism. The test is called StranDx, and it was developed by Linus Biotechnology Inc., a provider of precision exposome sequencing. StranDx analyzes the levels of chemicals in a child’s hair for a snapshot of their ‘exposome,’ which includes their environmental exposures and how they regulate certain essential nutrients. This sheds light on how a child’s physiology responds to their environment, which can predict the chances of autism.
FDA Grants ‘Breakthrough Device’ Status to Hair-Based Autism Test
The test analyzes chemical levels in a strand of a child’s hair to predict their chances of having autism.
Jan 21st, 2022